Monitor Q4 2026 for aficamten sNDA filing in non-obstructive HCM and MYQORZO revenue trajectory. The institutional cluster is split (buyers vs sellers) and stale; next quarter's 13F will show whether the buying conviction held or reversed.
Drug in focus
CYTK drug pipeline →MYQORZO
▲ Bullish Named in this fund cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
- Next catalyst
- None dated
What to watchThe FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $55.14entry
- T+1 · 7d ago +1.89%α +2.25% · $56.18
- T+5 · 16h ago −3.57%α −1.88% · $53.17
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Seven institutional investors added or doubled CYTK positions in Q3 2026, accumulating $23.5M net, while three sellers reduced by $43.6M. The buying cluster follows strong Q3 MYQORZO revenue of $44.5M and a narrower net loss, but the 45-day reporting lag and absence of insider buying weaken the signal.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$20.1M
▲ Buyers (7)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Aberdeen Group | DOUBLED | +182.8% | $22.3M | $12.1M |
| Barclays | DOUBLED | +205% | $14.2M | $8.2M |
| Candriam S.c.a. | ADD | +39.3% | $40.8M | $3.1M |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citigroup | TRIM | -73.9% | $27.5M | -$22.0M |
| Bank Of Montreal /Can | NEAR_EXIT | -79.8% | $24.3M | -$20.5M |
| Great Lakes Advisors | TRIM | -41.3% | $2.0M | -$1.1M |
Key Facts
- 7 institutional buyers added $23.5M in net new CYTK positions during Q3 2026
- 3 institutional sellers reduced positions by $43.6M, led by Citigroup (-$22.0M) and Bank of Montreal (-$20.5M)
- Top buyers: Aberdeen Group (+$12.1M), Barclays (+$8.2M), Candriam (+$3.1M)
- All 10 institutions are asset managers; no activist, quant, or sovereign funds in the cluster
- Confluence score of 20/100 indicates no insider buying to corroborate the institutional accumulation
- Q3 2026 earnings (reported Nov 4) showed MYQORZO revenue of $44.5M and a narrower net loss of $190.1M
Financial Impact
7 institutions accumulated $23.5M in new positions while 3 reduced holdings by $43.6M, for a net institutional outflow of $20.1M
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- No insider buying corroborates the institutional accumulation (confluence score 20/100)
- Net institutional flow was negative ($20.1M outflow) despite 7 buyers, three large sellers dominated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CYTK-2026-Q3 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Viewing Entry $55.14 settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers